News

DENVER – Lung cancer survivor Kathy Weber raised more than $8,000 on behalf of the International Association for the Study of Lung Cancer (IASLC) Foundation to take second place in Team Draft’s 2016 Lung Cancer Survivors Super Bowl Challenge in her goal of helping others fight this disease. Getting second place in the fundraising drive earned Kathy and her family a trip to the NFL Pro Bowl in Hawaii on Jan. 31, 2016.

December 2015 - January 2016 Newsletter

With the closing of each year we should reflect on the successes we have had and challenges we have faced.

DENVER – The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another round of hope with the FDA’s rapid progression of lung cancer drug approvals – this time for alectinib (Alecensa, Roche/Genenetech) for patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) if their disease deteriorated after treatment with another therapy called crizotinib (Xalkori, Pfizer). Patients who could not tolerate treatment with crizotinib also qualify for use of alectinib.

DENVER – Lung cancer survivor Kathy Weber is using the strength she demonstrated during her recovery to accept a new challenge: Helping others. In order to help more attention and assistance to the International Association for the Study of Lung Cancer (IASLC) in its goal to conquer thoracic malignancies around the world, Kathy is taking part in Team Draft’s 2016 Lung Cancer Survivors Super Bowl Challenge, raising money to help further cancer research and create new ways to treat the disease.

DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased to hear of another approval by the U.S. Food and Drug Administration (FDA) that helps in the fight against lung cancer – the fourth in two months. The FDA approved necitumumab (PortrazzaTM) in combination with standard chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for their advanced disease.

November 2015 Newsletter

November is known in the U.S. for the holiday of “Thanksgiving,” celebrating the good fortunes of the previous year. The past year has seen continuing significant advances in the management of lung cancer, with more to come.

Pages